BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Aquila Investment Management LLC

Aquila Investment Management LLC grew its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report) by 62.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,000 shares of the biotechnology company’s stock after buying an additional 5,000 shares during the period. Aquila Investment Management LLC’s holdings in BioMarin Pharmaceutical were worth $1,253,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in BMRN. EFG Asset Management North America Corp. boosted its position in shares of BioMarin Pharmaceutical by 44.9% during the 3rd quarter. EFG Asset Management North America Corp. now owns 67,322 shares of the biotechnology company’s stock worth $5,957,000 after purchasing an additional 20,874 shares during the period. FMR LLC raised its holdings in shares of BioMarin Pharmaceutical by 30.4% in the 3rd quarter. FMR LLC now owns 713,797 shares of the biotechnology company’s stock valued at $63,157,000 after purchasing an additional 166,219 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of BioMarin Pharmaceutical by 4.9% in the 4th quarter. Nordea Investment Management AB now owns 11,594 shares of the biotechnology company’s stock valued at $1,121,000 after purchasing an additional 544 shares in the last quarter. National Bank of Canada FI raised its stake in BioMarin Pharmaceutical by 3,233.6% during the 3rd quarter. National Bank of Canada FI now owns 610,911 shares of the biotechnology company’s stock worth $53,192,000 after acquiring an additional 592,585 shares in the last quarter. Finally, EULAV Asset Management raised its stake in BioMarin Pharmaceutical by 38.9% during the 3rd quarter. EULAV Asset Management now owns 132,036 shares of the biotechnology company’s stock worth $11,683,000 after acquiring an additional 37,000 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BMRN shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 price target on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Stifel Nicolaus reissued a “buy” rating and set a $101.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, December 21st. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $100.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Robert W. Baird lowered their target price on shares of BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating on the stock in a report on Tuesday, January 30th. Finally, Canaccord Genuity Group reissued a “hold” rating and set a $91.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 29th. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.61.

Check Out Our Latest Stock Report on BMRN

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $92.22 on Friday. The firm has a 50 day simple moving average of $87.46 and a 200-day simple moving average of $89.07. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.51 and a quick ratio of 1.57. The firm has a market cap of $17.40 billion, a PE ratio of 104.80, a P/E/G ratio of 1.76 and a beta of 0.31. BioMarin Pharmaceutical Inc. has a 1-year low of $76.02 and a 1-year high of $100.38.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $646.21 million during the quarter, compared to analyst estimates of $639.53 million. BioMarin Pharmaceutical had a net margin of 6.93% and a return on equity of 5.01%. The company’s revenue was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.11 earnings per share. On average, equities analysts expect that BioMarin Pharmaceutical Inc. will post 1.93 EPS for the current year.

Insider Activity

In related news, insider Henry J. Fuchs sold 35,341 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the completion of the transaction, the insider now owns 212,117 shares of the company’s stock, valued at $18,068,126.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 24,602 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $88.34, for a total transaction of $2,173,340.68. Following the completion of the sale, the executive vice president now directly owns 55,856 shares in the company, valued at $4,934,319.04. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Henry J. Fuchs sold 35,341 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the sale, the insider now owns 212,117 shares of the company’s stock, valued at $18,068,126.06. The disclosure for this sale can be found here. Insiders sold a total of 83,229 shares of company stock valued at $7,237,767 over the last 90 days. Insiders own 1.84% of the company’s stock.

BioMarin Pharmaceutical Profile

(Free Report)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Stories

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.